Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent (and give tissue if needed) to join the study
- You must have a biopsy showing classical Hodgkin lymphoma after your first-line treatment
- Your lymphoma must have come back or not responded after no more than one prior treatment step
- You should be well enough for treatment: ECOG 0–2 and blood counts meet minimum levels
- At least one tumor spot must be measurable on a PET/CT scan
- You are not able to have a stem cell transplant (for medical reasons, age, or preference)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
This trial tests a drug called brentuximab vedotin (BV) in people whose Hodgkin lymphoma has come back or not responded to treatment. It aims to see if BV can help shrink or control the cancer.
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
Hear when a new Relapsed Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.